Stock Analiz

NovoCure Ltd (NVCR) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

NovoCure’s revenue went from $83M in fiscal 2016 to $655M in fiscal 2025, growth of about 25.8% a year.

Net income in fiscal 2025 was -$136M, a net margin of -20.8%; the best year in this period was 2020 with $20M.

Over the twelve months to September 30, 2026, revenue was $725M and net income -$122M.

Free cash flow was -$76M in fiscal 2025 and positive in 4 of the 10 years shown.

The diluted share count rose 30% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $83M162017: $177M172018: $248M182019: $351M192020: $494M202021: $535M212022: $538M222023: $509M232024: $605M242025: $655M25$655M
Net income
2016: -$132M162017: -$62M172018: -$64M182019: -$7M192020: $20M202021: -$58M212022: -$93M222023: -$207M232024: -$169M242025: -$136M25-$136M
Free cash flow
2016: -$113M162017: -$40M172018: -$9M182019: $16M192020: $84M202021: $59M212022: $9M222023: -$100M232024: -$69M242025: -$76M25-$76M
EPS (diluted)
2016: $-1.54162017: $-0.70172018: $-0.69182019: $-0.07192020: $0.18202021: $-0.56212022: $-0.88222023: $-1.95232024: $-1.56242025: $-1.2225$-1.22

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$725M$655M$605M$509M$538M$535M$494M$351M$248M$177M$83M
Gross profit$559M$488M$468M$381M$423M$420M$388M$263M$168M$121M$37M
Operating income-$125M-$154M-$170M-$233M-$90M-$44M$30M-$914000-$34M-$39M-$115M
Net income-$122M-$136M-$169M-$207M-$93M-$58M$20M-$7M-$64M-$62M-$132M
EPS (diluted)$-1.06$-1.22$-1.56$-1.95$-0.88$-0.56$0.18$-0.07$-0.69$-0.70$-1.54
R&D$229M$225M$210M$223M$206M$201M$132M$79M$51M$38M$41M
Revenue growth—+8.3%+18.8%−5.3%+0.5%+8.2%+40.7%+41.6%+40.1%+113.6%+150.5%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$722000-$49M-$26M-$73M$31M$83M$99M$27M-$2M-$33M-$108M
Capital spending-$24M-$27M-$43M-$27M-$21M-$24M-$15M-$10M-$7M-$7M-$6M
Free cash flow-$25M-$76M-$69M-$100M$9M$59M$84M$16M-$9M-$40M-$113M
Dividends paid—————————$0$0
Buybacks———————————
Stock-based pay$117M$105M$160M$116M$107M$95M$76M$52M$40M$27M$22M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$448M$960M$911M$969M$938M$843M$326M$246M$183M$220M
Debt—$248M$683M$604M$590M$582M$451M$168M$149M$97M$96M
Equity—$340M$360M$362M$441M$410M$477M$218M$112M$114M$142M
Total assets—$804M$1.2B$1.1B$1.2B$1.1B$1.1B$479M$340M$265M$282M
Shares (diluted)117M111M108M106M105M103M109M97M92M89M86M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin77.0%74.5%77.3%74.8%78.6%78.5%78.5%74.8%67.7%68.6%44.2%
Operating margin-17.2%-23.5%-28.2%-45.7%-16.6%-8.3%6.2%-0.3%-13.6%-22.2%-139.1%
Net margin-16.8%-20.8%-27.9%-40.6%-17.2%-10.9%4.0%-2.1%-25.6%-34.8%-159.1%
FCF margin-3.4%-11.6%-11.4%-19.7%1.8%10.9%17.0%4.6%-3.5%-22.9%-136.7%
ROIC—-26.1%-12.9%-19.0%-6.9%-3.5%2.6%-0.2%-10.2%-14.7%-38.2%
ROE—-40.0%-46.8%-57.1%-21.0%-14.2%4.2%-3.3%-56.6%-54.3%-92.6%

Frequently asked questions

What is NovoCure’s annual revenue?

$655M in fiscal 2025 and $725M over the twelve months to September 30, 2026.

How much profit does NovoCure make?

Net income was -$136M in fiscal 2025 (net margin -20.8%).

Is NovoCure’s revenue growing?

Yes: revenue rose 8.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.